Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma 23Neoplasms, Plasma Cell 21Leukemia 21Recurrence 20Burkitt Lymphoma 18Lymphoma, Non-Hodgkin 15Neoplasms 14Lymphoma, Mantle-Cell 14Immunoglobulin Light-chain Amyloidosis 14Nausea 13Lymphoma, Large B-Cell, Diffuse 13Vomiting 12Breast Neoplasms 12Hodgkin Disease 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Amyloidosis 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Smoldering Multiple Myeloma 7Neoplasm Metastasis 7Leukemia, Biphenotypic, Acute 6Hematologic Neoplasms 6Blast Crisis 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, B-Cell 5

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Proteostasis Deficiencies × Calcium Dobesilate × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡